Agenus Restructures Its Remaining Convertible Notes
February 24, 2011 12:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that it has restructured and extended the maturity of its 8.00% senior secured convertible notes to August...
Agenus Reports Fourth Quarter and Year End 2010 Financial Results
February 17, 2011 07:00 ET
|
Agenus Inc.
Agenus Inc. (Nasdaq:AGEN) reported today its results for the fourth quarter and year ended December 31, 2010.
The company incurred a net loss attributable to common stockholders of $2.6 million,...
Agenus to Report Fourth Quarter and Year-End 2010 Financial Results on February 17, 2011; Conference Call to Follow
February 10, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its fourth quarter and full-year financial results before the market opens on February 17, 2011.
Agenus...
Agenus Announces Research Collaboration With Memorial Sloan-Kettering Cancer Center
January 24, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Jan. 24, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus'...
Agenus Regains Compliance With NASDAQ Listing Requirements
January 14, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Jan. 14, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) (formerly Antigenics Inc.) today announced that it has received notice from the Listing Qualifications Staff of The...
Antigenics Changes Company Name to Agenus
January 06, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Jan. 6, 2011 (GLOBE NEWSWIRE) -- Antigenics Inc. (Nasdaq:AGEN) today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to...
Antigenics Awarded Qualifying Therapeutic Discovery Project Grants
November 04, 2010 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 4, 2010 (GLOBE NEWSWIRE) -- Antigenics Inc. (Nasdaq:AGEN) today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project...
Antigenics Reports Third Quarter 2010 Financial Results
October 28, 2010 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 28, 2010 (GLOBE NEWSWIRE) -- Antigenics Inc. (Nasdaq:AGEN) reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to...
Antigenics Announces Expansion of Phase 2 Trial in Glioma
October 25, 2010 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Antigenics, Inc. (Nasdaq:AGEN) today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen),...
Antigenics to Report Third Quarter Financial Results on October 28, 2010; Conference Call to Follow
October 21, 2010 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 21, 2010 (GLOBE NEWSWIRE) -- Antigenics Inc. (Nasdaq:AGEN) will release its third quarter financial results before the market opens on October 28, 2010.
Antigenics executives...